4//SEC Filing
O'Kane Kieran 4
Accession 0000905148-26-000251
CIK 0001439725other
Filed
Jan 19, 7:00 PM ET
Accepted
Jan 20, 4:21 PM ET
Size
9.2 KB
Accession
0000905148-26-000251
Insider Transaction Report
Form 4
BIODESIX INCBDSX
O'Kane Kieran
Chief Commercial Officer
Transactions
- Exercise/Conversion
Common Stock
[F1]2026-01-15+805→ 8,167 total - Sale
Common Stock
[F2][F3]2026-01-16$8.15/sh−298$2,428→ 7,869 total - Exercise/Conversion
Restricted Stock Units
[F1][F4][F5]2026-01-15−805→ 1,609 total→ Common Stock (805 underlying)
Footnotes (5)
- [F1]Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
- [F2]These shares of the Issuer's Common Stock were sold automatically to cover taxes upon the vesting of RSUs.
- [F3]The price reported in Column 4 is a weighted average price of all shares sold on the transaction date by the Issuer's broker to cover taxes upon the vesting of RSUs for certain employees of the Issuer, including the Reporting Person. These shares were sold in multiple transactions at prices ranging from $8.10 to $8.28, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F4]These numbers have been adjusted to reflect the one-for-twenty reverse stock split effective September 15, 2025.
- [F5]These RSUs vest in a series of four successive equal annual installments measured from January 15, 2024, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date.
Signature
/s/ Robin H. Cowie as Attorney-in-Fact for Kieran O'Kane|2026-01-20
Documents
Issuer
BIODESIX INC
CIK 0001439725
Entity typeother
Related Parties
1- filerCIK 0001828131
Filing Metadata
- Form type
- 4
- Filed
- Jan 19, 7:00 PM ET
- Accepted
- Jan 20, 4:21 PM ET
- Size
- 9.2 KB